Liquid Biopsy Markets, 2029 - Exploring Screening, Diagnostic, and Therapy Selection Opportunities
Explore the evolving landscape of cancer diagnostics with our comprehensive report, analyzing screening, diagnostic, and therapy selection markets. Discover potential growth by cancer type and region, with insights into circulating tumor cells, cell-free DNA, and exosomes. Forecasts and valuations empower informed decisions.
Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product with Price and Volume Outlook, Including Executive and Consultant Guides 2025-2029" has been added to ResearchAndMarkets.com's offering.
Explore the dynamic landscape of the Screening, Diagnostic, Therapy Selection, Minimal Residual Disease, and Screening Market through our comprehensive report, which provides a detailed analysis of price and volume outlooks across different types of cancer.
Discover the transformative advancements in cancer diagnostics, particularly the innovative use of in vitro blood testing to detect cancer DNA, paving the way for widespread cancer screening tests. This cutting-edge technology is advancing rapidly, outpacing market growth, and offers a less invasive alternative to traditional surgical biopsies, poised to revolutionize disease diagnosis and monitoring.
The report delves into the growth phase of the market, offering insights into its substantial impact on the healthcare industry. It includes a five-year forecast of market size expansion, with detailed projections segmented by country, cancer type, and usage categories-ranging from screening, diagnosis, therapy selection, to recurrence monitoring.
Our analysis provides a granular breakdown for 15 countries and 4 regions, alongside specific insights on cancers such as Lung, Breast, Colorectal, Prostate, Cervical, and others. It also explores opportunities and challenges within screening, early detection, diagnostic, therapy monitoring, and recurrence monitoring realms, equipping stakeholders with essential knowledge for making informed investment decisions and accurate market valuations.
Capitalizing on the exhaustive market intelligence contained within, this report empowers decision-makers to confidently navigate the evolving cancer diagnostics landscape, leveraging unprecedented technological advancements to enhance patient outcomes and streamline healthcare processes.
Key Topics Covered:
1 Market Guides1.1 Liquid Biopsy Market - Strategic Situation Analysis1.2 Guide for Executives, Marketing, Sales, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors1.4 Impact of Artificial Intelligence on Liquid Biopsy Market2 Introduction and Market Definition2.1 What is Liquid Biopsy?2.2 The Sequencing Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry3 Market Overview3.1 Players in a Dynamic Market3.2 Using Biopsies3.3 Biopsy Sites3.4 The Situation Today - Biopsy Analysis3.5 Evidence of Cancer - Liquid Biopsy Technology3.6 Cancer Treatment Protocol Under Siege3.7 Structure of Industry Plays a Part4 Market Trends4.1 Factors Driving Growth4.1.1 Non-Invasive Game Changer4.1.2 Lower Cost4.1.3 Greater Accuracy4.1.4 Wide Range of Potential Uses4.1.5 Aging Population4.2 Factors Limiting Growth4.2.1 Lower prices4.2.2 Lack of Standards4.2.3 Protocol Resistance4.2.4 Initial Adoption Cost4.2.5 Conclusion4.3 Instrumentation and Automation4.3.1 Instruments Key to Market Share4.3.2 Bioinformatics Plays a Role4.4 Diagnostic Technology Development4.4.1 Next Generation Sequencing Fuels a Revolution4.4.2 Impact of NGS on pricing4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment4.4.4 CGES Testing, A Brave New World4.4.5 Biochips/Giant magneto resistance based assay5 Liquid Biopsy Recent Developments5.1 Recent Developments - Importance and How to Use This Section5.1.1 Importance of These Developments5.1.2 How to Use This Section5.2 Liquid Biopsy Firm QCDx Closes Financing5.3 LabCorp Launches Liquid Biopsy5.4 OncoHelix, AstraZeneca to Provide Prostate Cancer Liquid Biopsy Testing5.5 Liquid Biopsy Developer Oxford Cancer Analytics Raises $11M5.6 GeneCentric Therapeutics Launches ExpressCT Liquid Biopsy Platform5.7 Syantra Closes Financing5.8 Concerns Over Grail Test Effectiveness5.9 Guardant Health Sues Tempus for Patent Infringement5.10 Delfi Dx Liquid Biopsy Technology Shows Promise5.11 Thermo Fisher Scientific, Bayer to Develop NGS-Based CDx5.12 Grail Details TBE Method for Cancer Monitoring5.13 Naveris HPV Liquid Biopsy Test Gets Medicare Coverage5.14 Personalis NeXT Personal Dx Early-Access Program5.15 Liquid Biopsy Shortens Time to Treatment5.16 Guardant Health MRD Test Garners Coverage5.17 IMBdx, AstraZeneca Expand Prostate Cancer Liquid Biopsy Partnership5.18 FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic5.19 Epic Sciences Raises $24M for Breast Cancer Liquid Biopsy Test5.20 GenoMe Diagnostics Preparing DPCR-Based Ovarian Cancer Test5.21 Sophia Genetics to Commercialize Liquid Biopsy Test5.22 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx5.23 Liquid Biopsy Startup Haystack Oncology Raises $56M5.24 Hedera Dx to Launch Liquid Biopsy Streamlined Platform5.25 PamGene Expanding Liquid Biopsy Assays5.26 Liquid Biopsy Firm Hedera Dx Raises €14M5.27 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx5.28 Precision Oncology Dx Access Varies Widely in Europe5.29 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic5.30 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy5.31 BillionToOne Launches First Liquid Biopsy Products5.32 Dxcover Advances Multicancer Detection Platform5.33 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test5.34 Illumina Sues Guardant Health Over Patents5.35 Invitae to Expand Cancer Testing Portfolio5.36 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies5.37 IVBH Bio Takes Aim at With Liquid Biopsy Incubator5.38 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership5.39 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech5.40 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy5.41 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform5.42 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding5.43 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition5.44 Bio-Techne to Acquire Asuragen for up to $320M5.45 Personalis Broadens Liquid Biopsy Offering5.46 Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition5.47 Delfi Diagnostics Plans Multi-Cancer Screening Test5.48 Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response5.49 Liquid Biopsy NGS Panels - Diverse Test Claims5.50 CMS Colon Cancer Screening Memo Bodes Well for Assays5.51 Natera Liquid Biopsy Test Coverage to Expand5.52 Freenome Closes Financing to Support Early Cancer Detection Trial5.53 C$2.6M Liquid Biopsy Initiative5.54 NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy5.55 Liquid Biopsy Shows Promise as Screen for Cancers5.56 Inivata launches RaDaRT for the detection of residual disease and recurrence5.57 Liquid Biopsy Assay Detects 50+ Types of Cancer5.58 Liquid Biopsy Study Confirms Concordance with Tissue Biopsy6 Profiles of Key Players6.1 Admera Health, LLC6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Acuamark Diagnostics6.5 Agilent6.6 Amoy Diagnostics Co., Ltd.6.7 Anchor Dx6.8 ANGLE plc6.9 Applied DNA Sciences6.10 ARUP Laboratories6.11 AVIVA Systems Biology6.12 Baylor Miraca Genetics Laboratories6.13 Beckman Coulter Diagnostics (Danaher)6.14 Becton, Dickinson and Company6.15 Berkley Lights6.16 BGI Genomics Co. Ltd6.17 BillionToOne6.18 Bioarray Genetics6.19 Biocartis6.20 Biocept, Inc.6.21 Biodesix Inc.6.22 BioFluidica6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Techne6.28 Bioview6.29 Burning Rock6.30 Cardiff Oncology6.31 CareDx6.32 Caris Molecular Diagnostics6.33 CellCarta6.34 CellMax Life6.35 Cepheid (Danaher)6.36 Circulogene6.37 Cizzle Biotech6.38 Clearbridge Biomedics6.39 Clinical Genomics6.40 Cytolumina Technologies Corp.6.41 Datar Cancer Genetics Limited6.42 Diagnologix LLC6.43 Dxcover6.44 Element Biosciences6.45 Enzo Biochem6.46 Epic Sciences6.47 Epigenomics AG6.48 Eurofins Scientific6.49 Exact Sciences6.50 Fluxion Biosciences (Cell Microsystems)6.51 Freenome6.52 Fyr Diagnostics6.53 GeneFirst Ltd.6.54 Genetron Holdings6.55 GILUPI Nanomedizin6.56 Guardant Health6.57 HansaBiomed6.58 Haystack Oncology (Quest Dx)6.59 iCellate6.60 ICON PLC6.61 Illumina6.62 Incell Dx6.63 Inivata6.64 INOVIQ6.65 Invitae Corporation6.66 J&J Innovative Medicine6.67 Lucence Health6.68 Lunglife AI Inc6.69 MDNA Life SCIENCES, Inc.6.70 MDx Health6.71 Menarini Silicon Biosystems6.72 Mesa Laboratories, Inc.6.73 Millipore Sigma6.74 Miltenyi Biotec6.75 miR Scientific6.76 Myriad Genetics6.77 Nanostring6.78 NantHealth, Inc.6.79 Natera6.80 NeoGenomics6.81 Novogene6.82 On-Chip Biotechnologies6.83 Oncocyte6.84 OncoDNA6.85 Oncimmune6.86 Oxford Nanopore Technologies6.87 PamGene6.88 Panagene6.89 Personalis6.90 PGDx (Labcorp)6.91 PrecisionMed6.92 Predicine6.93 Predictive Oncology6.94 Prenetics6.95 Promega6.96 Qiagen6.97 Rarecells SAS6.98 RareCyte6.99 Revvity6.100 Roche Diagnostics6.101 Saga Diagnostics6.102 Screencell6.103 Siemens Healthineers6.104 simfo GmbH6.105 Singlera Genomics Inc.6.106 Singular Genomics6.107 Standard BioTools6.108 Stilla Technologies6.109 Superfluid Dx6.110 Sysmex Inostics6.111 Tempus Labs, Inc.6.112 Thermo Fisher Scientific6.113 Todos Medical6.114 Ultima Genomics6.115 Veracyte6.116 VolitionRX6.117 Vortex Biosciences7 The Global Market for Liquid Biopsy Diagnostics7.1 Global Market Overview by Country7.2 Global Market by Cancer - Overview7.3 Global Market by Usage - Overview7.4 Global Market by Place - Overview7.5 Global Market by Marker - Overview7.6 Global Market by Product - Overview8 Global Liquid Biopsy Diagnostic Markets - By Cancer8.1 Breast8.2 Colorectal8.3 Cervical8.4 Lung8.5 Prostate9 Global Liquid Biopsy Diagnostic Markets - by Usage9.1 Screening9.3 Diagnostic9.4 Therapy9.5 Monitor10 Global Liquid Biopsy Diagnostic Markets - by Place10.1 Hospital Lab10.2 Lab Service10.3 Lab Outpatient11 Global Liquid Biopsy Diagnostic Markets - by Marker11.1 Circulating Tumor Cell11.2 Cell Free DNA11.3 Vesicle12 Global Liquid Biopsy Diagnostic Markets - by Product12.1 Kits12.2 Instruments12.3 Service13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule
For more information about this report visit https://www.researchandmarkets.com/r/wtlj66
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
By GlobeNewswire Published on June 13, 2025, 11:30 IST Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025 , on June 16, in Boston, US; , on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group ), on June 18, in Paris, France; (hosted by ), on June 18, in Paris, France; International Neoantigen Summit , on June 24, 2025, in Amsterdam, Netherlands; , on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC. With its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Additional information about Transgene is available at: Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_EN Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Insider
4 hours ago
- Business Insider
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ('CERo'), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the 'Investors') pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. 'We welcome this vote of confidence and the continued support of our investors as we continue to show progress along our clinical timeline. The completion of our first-in-human dosing represents a significant clinical development milestone in AML for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L, and we will continue to communicate results as the data matures,' said Chris Ehrlich, Chief Executive Officer. The gross proceeds to CERo from today's closing are expected to be approximately $750,000, with up to $2.25 million of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236,for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Business Insider
4 hours ago
- Business Insider
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share (the 'Common Stock'). The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 13, 2025, and the Company's Common Stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market ('Nasdaq') as of the opening of trading on June 13, 2025. The CUSIP number of 71902K402 will be assigned to the Company's Common Stock when the reverse stock split becomes effective. When the reverse stock split becomes effective, every twenty (20) of the Company's issued shares of Common Stock will be combined into one issued share of Common Stock, without any change to the par value per share. This will reduce the number of outstanding shares of Common Stock from approximately 10,321,839 shares to approximately 516,092 shares. Proportional adjustments will also be made to the number of shares of Common Stock awarded and available for issuance under the Company's equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company's outstanding stock options and other equity securities under the Company's equity incentive plans. Additionally, all outstanding shares of preferred stock will be adjusted in accordance with their terms, which will, among other changes to the preferred stock terms, result in proportionate adjustments being made to the number of shares issuable upon conversion of such preferred stock and to the conversion prices of such preferred stock. All outstanding warrants will also be adjusted in accordance with their terms, which will, among other changes to the warrant terms, result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise and redemption prices of such warrants. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise hold a fraction of a share of Common Stock of the Company will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share. Stockholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the consequence of the reverse stock split reflected in their accounts on or after June 13, 2025. Such beneficial holders may contact their bank, broker, or nominee for more information. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of the Company at the 2025 Annual Meeting of Stockholders of the Company held on May 29, 2025. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies. This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo the timing and completion of the reverse stock split, and the acceptance and implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and its subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
